Biofrontera Stock Price, News & Analysis

Biofrontera Inc. (Nasdaq: BFRI) will present at the LD Micro Main Event XV on October 26, 2022, at 4:00 PM Pacific Time at the Luxe Sunset Boulevard Hotel, Los Angeles, CA. CEO Erica Monaco will discuss the company’s dermatological products, focusing on photodynamic therapy and topical antibiotics for treating conditions like actinic keratoses and impetigo. A live webcast will be available at this link, and archived later on their website.

Biofrontera (Nasdaq: BFRI) announces its sponsorship of the Fall Clinical Dermatology Conference from October 20-23 in Las Vegas. As a Gold Industry Sponsor, the company will host an exhibit showcasing its flagship drug, Ameluz, and other products. An Advisory Board meeting will enhance education on photodynamic therapy (PDT) among dermatologists. Four research posters related to Ameluz will be presented, highlighting clinical trials and their findings. CEO Erica Monaco emphasizes the importance of these events in advancing knowledge and product visibility.

Biofrontera Inc. (Nasdaq: BFRI) announced the adoption of a limited duration shareholder rights plan to protect shareholder interests. This plan allows for the distribution of one preferred stock purchase right for each share of common stock to shareholders of record on October 24, 2022. The Board believes the current stock price does not reflect the company’s intrinsic value and aims to safeguard against unsolicited offers. The rights become exercisable upon acquisition of 20% or more of the common stock. The plan will expire on October 13, 2023.

Biofrontera Inc. (NASDAQ: BFRI) announced its participation in Renmark Financial Communications’ live Virtual Non-Deal Roadshow Series. The presentations will occur on October 14 at 10:00 AM EDT and October 18 at 1:00 PM CDT, discussing the latest investor presentation and allowing for a live Q&A session. CEO Erica Monaco stated this is the first of multiple events aimed at engaging investors across the U.S. Registrations are available through the provided links, with replays accessible on the company's investor page.

Biofrontera (Nasdaq: BFRI) reported preliminary unaudited product revenues for Q3 2022 at approximately $4.3 million, consistent with Q3 2021. For the first nine months of 2022, revenues are expected to be around $18.5 million, showing a 24% increase year-over-year. The company aims for at least a 30% revenue increase in 2022. CEO Erica Monaco highlighted ongoing efforts to enhance the adoption of PDT for actinic keratosis treatments, despite Q3 typically being a softer sales quarter. Full financial results will be disclosed in November 2022.

Biofrontera Inc. (Nasdaq: BFRI) has announced that CEO Erica Monaco will present at the Roth Inaugural Healthcare Opportunities Conference on October 6, 2022, at 8:30 a.m. Eastern Time in New York City. The company invites investors attending the conference to schedule one-on-one meetings with management.

Biofrontera specializes in dermatological products, focusing on treatments like photodynamic therapy and topical antibiotics for conditions such as actinic keratoses and impetigo.

Biofrontera (Nasdaq: BFRI) announced that its Ameluz® marketing campaign has received two awards from PM360: “Relaunch/Revitalization of the Year” and “Professional Website/Online Initiative of the Year.” The awards were presented at the 14th Annual Trailblazer Awards on September 22, 2022. The campaign, titled “Danger Lurks Below the Surface,” aimed to raise awareness of actinic keratoses (AK). CEO Erica Monaco emphasized the campaign's impact on revenue growth and brand awareness in the PDT market. The Ameluz campaign has also earned recognition from other industry awards.

Biofrontera (Nasdaq: BFRI) announced the appointment of Gerard DiGirolamo as National Sales Director, effective September 13, 2022. In this newly created role, DiGirolamo will oversee U.S. sales strategies and recruitment for the company’s dermatological products, including Ameluz® and BF-RhodoLED®.

With over 25 years of experience, he previously served as Vice President of Sales at Verrica Pharmaceuticals. His expertise in dermatology and established industry relationships are expected to enhance Biofrontera's commercial initiatives, including the launch of BF-RhodoLED XL®.

Biofrontera Inc. (Nasdaq: BFRI) announced the USPTO's notice of allowance for patent application No. 12/520,759, related to a novel nanoemulsion formulation. This patent covers compositions improving stability and cell penetration for dermatological treatments, enhancing the efficacy of Ameluz®. The company has also received a special designation for expedited review of a patent on novel photodynamic therapy (PDT) illumination protocols, further reinforcing its market position. This positions Biofrontera to broaden its offerings in dermatological treatments.